Elidel: Advanced Non-Steroidal Eczema Treatment
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 1 | $43.00 | $43.00 (0%) | 🛒 Add to cart |
| 2 | $38.70 | $86.00 $77.40 (10%) | 🛒 Add to cart |
| 3 | $34.40 | $129.00 $103.20 (20%) | 🛒 Add to cart |
| 4 | $32.25 | $172.00 $129.00 (25%) | 🛒 Add to cart |
| 5 | $29.24 | $215.00 $146.20 (32%) | 🛒 Add to cart |
| 6 | $25.80 | $258.00 $154.80 (40%) | 🛒 Add to cart |
| 7 | $23.34 | $301.00 $163.40 (46%) | 🛒 Add to cart |
| 8 | $21.50 | $344.00 $172.00 (50%) | 🛒 Add to cart |
| 9 | $20.07 | $387.00 $180.60 (53%) | 🛒 Add to cart |
| 10 | $18.92
Best per tube | $430.00 $189.20 (56%) | 🛒 Add to cart |
Synonyms | |||
Elidel (pimecrolimus) is a prescription topical immunomodulator specifically formulated for the management of mild to moderate atopic dermatitis (eczema) in non-immunocompromised patients aged 2 years and older. As a calcineurin inhibitor, it works by selectively targeting inflammatory pathways without the skin-thinning risks associated with prolonged corticosteroid use. This non-steroidal mechanism offers a valuable therapeutic alternative for sensitive skin areas and long-term maintenance therapy. Clinical studies demonstrate its efficacy in reducing pruritus, erythema, and lesion severity while maintaining a favorable safety profile.
Features
- Contains 1% pimecrolimus as active pharmaceutical ingredient
- Available in 30g, 60g, and 100g tubes of white cream formulation
- Non-greasy, fragrance-free emulsion base for optimal skin compatibility
- pH-balanced formulation minimizes irritation potential
- Preservative-free in tube packaging to maintain stability
- Rapid absorption with minimal systemic exposure
- Suitable for application on face, neck, and other sensitive areas
Benefits
- Provides targeted anti-inflammatory action without corticosteroid side effects
- Reduces itching and inflammation within days of initiation
- Minimizes risk of skin atrophy, striae, and telangiectasia associated with long-term steroid use
- Suitable for intermittent long-term therapy in appropriate patients
- Allows treatment of delicate skin areas (eyelids, face, neck folds)
- Helps restore skin barrier function with consistent use
- May reduce frequency of eczema flares when used at earliest signs
Common use
Elidel is primarily indicated for the short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in patients who:
- Have not responded adequately to conventional therapies
- Require alternative to topical corticosteroids
- Experience corticosteroid-associated adverse effects
- Require treatment of sensitive skin areas (face, neck, intertriginous areas)
- Need maintenance therapy to prevent disease exacerbation
Dosage and direction
Apply a thin layer of Elidel cream twice daily to affected skin areas. Use the minimal amount needed to control symptoms. Gently rub into the skin until absorbed. Treatment should begin at earliest signs or symptoms of atopic dermatitis. Continue use until complete clearance of signs/symptoms. If signs and symptoms persist beyond 6 weeks, re-evaluate diagnosis. Wash hands after application unless hands are treatment areas. Not for ophthalmic use.
Precautions
- For external use only; avoid contact with eyes and mucous membranes
- May cause application site reactions (burning, warmth, itching)
- Minimize exposure to natural and artificial sunlight (tanning beds, UV lamps)
- Wear protective clothing and use broad-spectrum sunscreen during treatment
- Not recommended for use under occlusive dressings
- Use in immunocompromised patients has not been established
- Long-term safety beyond one year of intermittent use not established
- Monitor patients for lymph node enlargement during extended use
Contraindications
- Hypersensitivity to pimecrolimus or any component of the formulation
- Patients with Netherton’s syndrome or other skin barrier defects
- Active cutaneous viral infections (herpes simplex, varicella zoster)
- Treatment of clinically infected atopic dermatitis without concomitant anti-infective therapy
- Use in children under 2 years of age
- Patients with congenital or acquired immunodeficiencies
- Application to malignant or premalignant skin conditions
Possible side effects
Very common (>10%):
- Application site burning (especially during first few days)
- Application site irritation/itching
Common (1-10%):
- Skin infection (folliculitis, impetigo)
- Headache
- Application site warmth/redness
- Increased sensitivity to hot/cold temperatures
- Herpes simplex infections
- Skin papilloma/warts
Uncommon (0.1-1%):
- Alcohol intolerance (facial flushing, skin irritation)
- Lymph node enlargement
- Conjunctivitis
- Eyelid irritation
- Rosacea
Rare (<0.1%):
- Anaphylactoid reactions
- Skin discoloration
- Photosensitivity reactions
- Malignancies (causal relationship not established)
Drug interaction
- No formal drug interaction studies conducted
- Theoretical potential for interaction with other CYP3A4 inhibitors
- Caution with concomitant use of other immunosuppressive agents
- May enhance effects of alcohol consumption (facial flushing)
- No known interactions with vaccines, but avoid application near vaccination sites
- Minimal systemic absorption reduces likelihood of significant interactions
Missed dose
Apply missed dose as soon as remembered, unless it is almost time for the next scheduled application. Do not apply double dose to make up for missed application. Maintain twice-daily dosing schedule consistently for optimal therapeutic effect. If multiple doses missed, resume regular dosing schedule without compensation.
Overdose
Topical overdose is unlikely due to minimal systemic absorption. Excessive application may increase incidence of local adverse effects. If accidental ingestion occurs, gastric lavage and symptomatic treatment may be considered. No specific antidote exists. Monitor for systemic effects including headache, nausea, or vomiting. Maintain adequate hydration if gastrointestinal symptoms occur.
Storage
Store at room temperature (15-30°C). Do not freeze. Keep tube tightly closed when not in use. Protect from excessive heat and direct sunlight. Discard any cream that has changed color or consistency. Keep out of reach of children. Do not use beyond expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Treatment decisions should be made by qualified healthcare providers based on individual patient circumstances. Patients should read the official prescribing information and discuss any concerns with their physician. Safety and efficacy in pregnancy and lactation have not been established—use only if potential benefit justifies potential risk.
Reviews
Clinical Study Data: Multiple randomized controlled trials demonstrate 51-61% of patients achieving clear or almost clear skin after 6 weeks of treatment. Pediatric studies show significant improvement in EASI scores compared to vehicle. Long-term studies (1 year) indicate maintained efficacy with intermittent use.
Expert Consensus: Dermatology guidelines position Elidel as second-line therapy for mild-to-moderate atopic dermatitis, particularly for sensitive areas and patients requiring non-steroidal options. The American Academy of Dermatology recognizes its role in proactive therapy for flare prevention.
Patient Reports: Users frequently report rapid itch relief within 2-3 days of initiation. Many appreciate the non-greasy formulation and absence of steroid-related concerns. Some note initial burning sensation that typically resolves within first week of use.